Atara Biotherapeutics (ATRA) shares rallied 10% in the last trading session to close at $14.26. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 2.6% gain over the past four weeks.
The price rise can be attributed to growing investor optimism regarding Atara’s recent development related to its lead product candidate, tabelecleucel (tab-cel), a novel T-cell immunotherapy, which has been developed for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). The company’s resubmitted biologics license application for tab-cel is under priority review in the United States and a decision from the FDA is due on Jan. 10, 2026.
This drug developer is expected to post quarterly loss of $0.83 per share in its upcoming report, which represents a year-over-year change of +71.7%. Revenues are expected to be $1.29 million, down 96.8% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Atara Biotherapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ATRA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Atara Biotherapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Amicus Therapeutics (FOLD), another stock in the same industry, closed the last trading session 2.3% higher at $8.35. FOLD has returned 8.5% in the past month.
Amicus Therapeutics' consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.12. Compared to the company's year-ago EPS, this represents a change of +20%. Amicus Therapeutics currently boasts a Zacks Rank of #3 (Hold).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Atara Biotherapeutics, Inc. (ATRA): Free Stock Analysis Report Amicus Therapeutics, Inc. (FOLD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
